Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$133M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$93.9M |
| 4 |
Amazon
AMZN
|
+$91.8M |
| 5 |
Otis Worldwide
OTIS
|
+$84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$226M |
| 2 |
RTN
Raytheon Company
RTN
|
+$145M |
| 3 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$51.2M |
| 4 |
Newmont
NEM
|
+$50.7M |
| 5 |
Yum! Brands
YUM
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.6% |
| 2 | Healthcare | 15.16% |
| 3 | Consumer Discretionary | 12.49% |
| 4 | Communication Services | 10.41% |
| 5 | Industrials | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Emergent Biosolutions
EBS
$230M
| $7.8M | 0.01% |
98,700
+13,600
| +16% | +$1.01M |
|
902
Power Integrations
POWI
$3.48B
| $7.79M | 0.01% |
131,800
+17,600
| +15% | +$925K |
|
|
SGI
903
Somnigroup International
SGI
$14B
| $7.79M | 0.01% |
432,800
+76,400
| +21% | +$1.1M |
|
|
NEWR
904
DELISTED
New Relic, Inc.
NEWR
| $7.75M | 0.01% |
112,497
+15,600
| +16% | +$932K |
|
905
Texas Roadhouse
TXRH
$13.6B
| $7.74M | 0.01% |
147,200
+19,300
| +15% | +$941K |
|
906
Semtech
SMTC
$12.4B
| $7.72M | 0.01% |
147,900
+18,900
| +15% | +$884K |
|
907
Qualys
QLYS
$6.78B
| $7.72M | 0.01% |
74,200
+10,400
| +16% | +$1.09M |
|
|
GBT
908
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $7.71M | 0.01% |
122,200
+5,400
| +5% | +$370K |
|
909
Caesars Entertainment
CZR
$6.04B
| $7.71M | 0.01% |
192,544
+64,300
| +50% | +$1.78M |
|
|
DOC
910
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $7.71M | 0.01% |
439,806
+74,500
| +20% | +$1.21M |
|
911
PVH
PVH
$3.77B
| $7.68M | 0.01% |
159,740
-128,100
| -45% | -$5.97M |
|
912
Lithia Motors
LAD
$8.32B
| $7.67M | 0.01% |
50,700
+6,800
| +15% | +$778K |
|
913
Stantec
STN
$8.44B
| $7.66M | 0.01% |
249,670
+32,200
| +15% | +$940K |
|
914
AXIS Capital
AXS
$7.3B
| $7.6M | 0.01% |
187,400
+24,600
| +15% | +$948K |
|
915
Unum
UNM
$14.7B
| $7.6M | 0.01% |
458,108
-342,400
| -43% | -$5.4M |
|
|
ETRN
916
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $7.59M | 0.01% |
913,387
+493,400
| +117% | +$3.88M |
|
917
SouthState Bank Corp
SSB
$10.8B
| $7.58M | 0.01% |
158,937
+93,535
| +143% | +$4.88M |
|
|
PRSP
918
DELISTED
Perspecta Inc. Common Stock
PRSP
| $7.54M | 0.01% |
324,400
+42,000
| +15% | +$916K |
|
919
Strategic Education
STRA
$1.86B
| $7.54M | 0.01% |
49,038
+6,400
| +15% | +$998K |
|
920
Marriott Vacations Worldwide
VAC
$4.17B
| $7.53M | 0.01% |
91,636
+22,300
| +32% | +$1.82M |
|
921
Integra LifeSciences
IART
$1.42B
| $7.53M | 0.01% |
160,194
+18,600
| +13% | +$914K |
|
922
Simpson Manufacturing
SSD
$8B
| $7.52M | 0.01% |
89,100
+11,700
| +15% | +$863K |
|
|
JHG
923
DELISTED
Janus Henderson
JHG
| $7.51M | 0.01% |
354,705
+45,600
| +15% | +$879K |
|
924
Spire
SR
$4.9B
| $7.49M | 0.01% |
114,050
+15,200
| +15% | +$1.08M |
|
925
Envista
NVST
$4.51B
| $7.49M | 0.01% |
355,300
+63,000
| +22% | +$1.18M |
|
Similar funds
Swiss National Bank's Q2 2020 Portfolio in Review
As of Q2 2020, Swiss National Bank held 2,599 positions worth $118B, up 26% from $94.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Swiss National Bank's Q2 2020 filing shows 119 new, 2,134 increased, 181 reduced and 161 closed positions. Its largest new stake was Otis Worldwide: 1,621,054 shares worth $92.2M. The largest sale was Allergan plc, an estimated $226M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2020 buy was Otis Worldwide: 1,621,054 shares worth $92.2M.
- Swiss National Bank added most to Alibaba in Q2 2020, an estimated $133M increase.
- Swiss National Bank's biggest Q2 2020 reduction was Newmont, cutting an estimated $50.7M.
- Swiss National Bank fully exited Allergan plc in Q2 2020, selling an estimated $226M.
- Swiss National Bank's ten largest holdings make up 24% of its $118B portfolio in Q2 2020.
- Swiss National Bank opened 119 new positions and closed 161 in Q2 2020.
- Swiss National Bank's portfolio value rose 26% quarter-over-quarter to $118B.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.